Laeeq Malik1, Helen Parsons2, Devalingam Mahalingam3, Benjamin Ehler2, Martin Goros2, Alex Mejia3, Andrew Brenner3, John Sarantopoulos3. 1. Institute for Drug Development, Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX. Electronic address: Malikl@uthscsa.edu. 2. Department of Epidemiology and Biostatistics, University of Texas Health Science Center, San Antonio, TX. 3. Institute for Drug Development, Cancer Therapy and Research Center (CTRC), University of Texas Health Science Center, San Antonio, TX.
Abstract
BACKGROUND/ INTRODUCTION: The purpose of this study was to describe the basic demographic characteristics, and analyze the response and survival experience of advanced renal cancer subjects treated in a phase I trial. PATIENTS AND METHODS: We conducted a retrospective observational study in 70 renal cancer patients participating in 25 phase I trials. Descriptive statistics, Kaplan-Meier, and multivariate Cox proportional hazards analyses were used to examine factors associated with time from study entry to treatment failure (TTF) and survival. RESULTS: The median age at diagnosis was 56.50 years. Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 23.19% (n = 16) of the patients; 49.18% (n = 30) had received 2 or more previous lines of systemic therapy; and 84.29% (n = 59) of patients had 2 or more metastatic sites. A median number of 4.00 cycles of treatment was delivered. Four partial responses (6.25%) and 38 cases of stable disease lasting > 4 months (43.75%) were observed. The median TTF was 16.00 weeks. In multivariate analyses, men and patients with lactate dehydrogenase > 1.5 times the upper limit of normal had a shorter TTF. The median overall survival was 45.57 weeks (319.00 days). In multivariate analysis, factors predicting shorter survival were ECOG performance status ≥ 1 (P = .023), age younger than 60 years (P = .015), albumin < 3.4 g/dL (P = .042), and liver metastases (P = .010). CONCLUSION: Advanced renal cancer patients with select clinical characteristics could consider phase I trials after exhausting standard therapeutic options.
BACKGROUND/ INTRODUCTION: The purpose of this study was to describe the basic demographic characteristics, and analyze the response and survival experience of advanced renal cancer subjects treated in a phase I trial. PATIENTS AND METHODS: We conducted a retrospective observational study in 70 renal cancerpatients participating in 25 phase I trials. Descriptive statistics, Kaplan-Meier, and multivariate Cox proportional hazards analyses were used to examine factors associated with time from study entry to treatment failure (TTF) and survival. RESULTS: The median age at diagnosis was 56.50 years. Eastern Cooperative Oncology Group (ECOG) performance status was 0 for 23.19% (n = 16) of the patients; 49.18% (n = 30) had received 2 or more previous lines of systemic therapy; and 84.29% (n = 59) of patients had 2 or more metastatic sites. A median number of 4.00 cycles of treatment was delivered. Four partial responses (6.25%) and 38 cases of stable disease lasting > 4 months (43.75%) were observed. The median TTF was 16.00 weeks. In multivariate analyses, men and patients with lactate dehydrogenase > 1.5 times the upper limit of normal had a shorter TTF. The median overall survival was 45.57 weeks (319.00 days). In multivariate analysis, factors predicting shorter survival were ECOG performance status ≥ 1 (P = .023), age younger than 60 years (P = .015), albumin < 3.4 g/dL (P = .042), and liver metastases (P = .010). CONCLUSION:Advanced renal cancerpatients with select clinical characteristics could consider phase I trials after exhausting standard therapeutic options.
Authors: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang Journal: J Natl Compr Canc Netw Date: 2009-06 Impact factor: 11.908
Authors: Brian I Rini; Bernard Escudier; Piotr Tomczak; Andrey Kaprin; Cezary Szczylik; Thomas E Hutson; M Dror Michaelson; Vera A Gorbunova; Martin E Gore; Igor G Rusakov; Sylvie Negrier; Yen-Chuan Ou; Daniel Castellano; Ho Yeong Lim; Hirotsugu Uemura; Jamal Tarazi; David Cella; Connie Chen; Brad Rosbrook; Sinil Kim; Robert J Motzer Journal: Lancet Date: 2011-11-04 Impact factor: 79.321
Authors: Elizabeth Atchison; John Eklund; Brenda Martone; Lili Wang; Adi Gidron; Gary Macvicar; Alfred Rademaker; Charles Goolsby; Laura Marszalek; James Kozlowski; Norm Smith; Timothy M Kuzel Journal: J Immunother Date: 2010-09 Impact factor: 4.456
Authors: Elizabeth Horstmann; Mary S McCabe; Louise Grochow; Seiichiro Yamamoto; Larry Rubinstein; Troy Budd; Dale Shoemaker; Ezekiel J Emanuel; Christine Grady Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins Journal: J Clin Oncol Date: 2010-01-25 Impact factor: 44.544